Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
t-TUCB is a soluble epoxide hydrolase (sEH) inhibitor (IC50s = 0.4, 3.1, and 11.9 nM for the human, mouse, and rat enzymes, respectively).1 It also inhibits fatty acid amide hydrolase (FAAH; IC50 = 260 nM for the human enzyme). t-TUCB (3 mg/kg) increases the mechanical paw withdrawal threshold in a mouse model of diabetic neuropathic pain induced by streptozotocin (Item No. 13104).1 It prevents EKG abnormalities induced by the β1- and β2-adrenergic receptor agonist isoproterenol (Item No. 15592), as well as reduces isoproterenol-induced increases in infarct size and heart weight, in a rat model of myocardial ischemia when administered at doses of 3, 10, and 30 mg/kg.2
WARNING This product is not for human or veterinary use.
1. Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive. Pharmacol. Res. 97, 7-15 (2015).
2. Soluble epoxide hydrolase inhibitor, t-